Supraventricular tachycardia (SVT) are a heterogeneous group of arrhythmias including atrial tachycardia, atrioventricular nodal re-entrant tachycardia, and atrioventricular reciprocating tachycardia. Because SVT increases patient morbidity, notably when frequent, and in some patient populations SVT can be life-threatening, accurate diagnosis and appropriate management are critical to improving patient quality of life.

Today, we are taking a look at the latest regarding SVT in relation to clinical guidance, FDA approvals, and clinical trials.

Current Supraventricular Tachycardia Guidance
Recent FDA Approvals for SVT

Below are the medications and therapies recently approved by the FDA that we anticipate being incorporated into future clinical guidelines: 

  • (Rapiblyk) landiolol
    • AOP Health
    • April 2026
    • For use in pediatric patients (from birth to <18 years of age) with supraventricular tachycardia (SVT).
  • (Cardamyst) etripamil
    • Milestone Pharmaceuticals
    • December 2025
    • For the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
  • (Rapiblyk) landiolol
    • AOP Orphan Pharmaceuticals
    • November 2024
    • For the treatment of the severe heart condition supraventricular tachycardia (atrial fibrillation and atrial flutter).
Latest Clinical Trials Related to SVT

The following are the latest clinical trials based in the United States that we anticipate may impact future SVT clinical guidelines.

Don't miss out on our other recently published cardiology-related content and be sure to sign up for alerts to keep up with the latest guidelines and insights.